CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Jan. 4, 2021-- Repare Therapeutics, Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics,
